Oncology Hub

Sep
30

Live Webcast:The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: Guidance for Today and the Path Forward

Tuesday, December 1, 2020  |  6:30 PM – 8:00 PM ET    In this CME Outfitters Live and OnDemand, integrations of animated 3-D models will provide visual representation of the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC to complement expert faculty insights and evidence supporting testing strategies to identify predictive biomarkers, emerging […]

Read More
DETAIL
Jun
24

Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape

Breast cancer (BC) is a heterogeneous disease with human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification observed in 20%-30% of cases. HER2-positive (+) BC correlates with poor clinical outcomes unless appropriately treated with targeted therapy. Despite significant therapeutic advances, many patients experience disease progression with resistance to targeted agents developing over the course […]

Read More
DETAIL
May
15

Real-World Evidence: Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer

Participate in this free CME Snack to hear Dr. Martine Piccart discuss randomized, controlled trials, real-world data, and real-world evidence, focusing on the current real-world evidence in the field of cylcin-dependent kinase (CDK) 4/6 inhibitors in metastatic breast cancer. Earn CME/CE credit in just 20 minutes!

Read More
DETAIL